Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02117115 · ClinicalTrials.gov registry record · Early Phase 1

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

A Early Phase 1 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Early Phase 1
Development phase
21
Enrollment target

NCT02117115 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02117115, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Early Phase 1
Development phase
21 participants
Enrollment target

Study Summary

Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant period, as defined by the risk of contrast-related nephropathy or allergic reaction.

Interventions

  • RADIATION Dynamic contrast-enhanced computed tomography
  • DRUG Ioversol

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2014-06
Est. Completion 2015-05
Phase Early Phase 1

What the Registry Record Tells You About NCT02117115

The ClinicalTrials.gov registry entry for NCT02117115 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dynamic contrast-enhanced computed tomography is the first listed.

NCT02117115 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02117115 about?

NCT02117115 is a clinical study titled "Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation". Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host disease. The primary endpoint is the feasibility and safety of contrast-en...

What is the current status of trial NCT02117115?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2014-06. Estimated completion is 2015-05.

What interventions are being tested in trial NCT02117115?

The interventions under investigation include: Dynamic contrast-enhanced computed tomography (RADIATION), Ioversol (DRUG).

Who is sponsoring clinical trial NCT02117115?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.